NeoStem Inc  

(Public, NASDAQ:NBS)   Watch this stock  
Find more results for NBS
3.58
-0.06 (-1.65%)
Real-time:   2:38PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.51 - 3.65
52 week 3.08 - 7.98
Open 3.64
Vol / Avg. 64,017.00/310,304.00
Mkt cap 131.63M
P/E     -
Div/yield     -
EPS -1.80
Shares 35.74M
Beta 1.16
Inst. own 17%
Feb 9, 2015
NeoStem Inc at Biotechnology Industry Organization CEO & Investor Conference - 10:00AM EST - Add to calendar
Jan 12, 2015
NeoStem Inc at EBD Biotech Showcase
Jan 12, 2015
NeoStem Inc at OneMedForum SF
Nov 25, 2014
NeoStem Inc at Deutsche Boerse German Equity Forum
Nov 4, 2014
NeoStem Inc at EBD Group BIO-Europe Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -417.13% -269.19%
Operating margin -394.84% -250.94%
EBITD margin - -239.99%
Return on average assets -52.05% -54.76%
Return on average equity -96.54% -81.45%
Employees 108 -
CDP Score - -

Address

SUITE 350, 420 LEXINGTON AVENUE
NEW YORK, NY 10170
United States - Map
+1-212-5844171 (Phone)
+1-646-5147787 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NeoStem, Inc. (NeoStem) is a provider of cellular therapy products. The Company is engaged in the development of cell therapy products; it also provides development and manufacturing services. NeoStem�s research and clinical development activities are aimed at three therapeutic platforms: ischemic repair (CD34 Cell Program), immune modulation (T Regulatory Cell Program) and tissue regeneration (VSELTM Technology). The Company develops therapies to address ischemia through its CD34 Cell Program. The Company focuses on the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs, restoring their normal function. The Company�s AMR-001 is the product candidate in its CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) (AMI).

Officers and directors

Robin L. Smith M.D. Executive Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Robert S. Vaters President, Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
David J. Mazzo Ph.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Robert A. Preti Ph.D. President and Chief Scientific Officer - PCT
Age: 57
Bio & Compensation  - Reuters
Stephen W. Potter Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Joseph Talamo Vice President, Chief Accounting Officer, Corporate Controller
Age: 45
Bio & Compensation  - Reuters
Catherine M. Vaczy Esq Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
David Schloss Vice President, Director of Human Resources
Age: 55
Bio & Compensation  - Reuters
David Altarac Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Andrew L. Pecora M.D. Chief Visionary Officer, Director
Age: 57
Bio & Compensation  - Reuters